Bristol-Myers Squibb to Present New Research Findings at the Annual EULAR 2018

Bristol-Myers Squibb Company today confirmed that 31 abstracts demonstrating the company’s immunoscience-research focus as well as how ORENCIA (abatacept) therapy may impact diverse patient subgroups will be presented at the Annual European Congress of Rheumatology (EULAR 2018), June 13-16 in Amsterdam. For more than two decades, Bristol-Myers Squibb has pioneered research into the body’s immune system aimed at discovering and developing medicines that harness immunomodulation to treat disease. The data to be presented at EULAR 2018 include analyses that provide new insights into immunomodulation treatment for RA with ORENCIA, as well as research that further explores the clinical significance of ACPA, particularly as a predictive biomarker indicative of a poor prognosis for patients with early highly active, progressive RA.

Among the Bristol-Myers Squibb data to be presented at EULAR 2018:

• Claims analysis demonstrating an association between patients with RA presenting elevated ACPA titers are susceptible to increased mortality rates in a real world setting. The full post hoc analysis will be featured in an oral presentation on Thursday, June 14, at 11:10 CEST.
• Analysis comparing abatacept with adalimumab on measures of sustained remission [DAS28 (CRP) <2.6] and showing seropositive patients with early, erosive RA may respond differently to targeted biologic therapy. The full post hoc analysis will be featured in a poster presentation on Saturday, June 16, from 10:30–12:00 CEST.
• Claims analysis (2006–2016) of abatacept-treated RA patients with greater risk factors for type 2 diabetes at baseline evaluating the risk for new-onset type 2 diabetes versus patients treated with other biological disease-modifying, anti-rheumatic drugs (bDMARDs). The full data analysis will be featured in a poster presentation on Thursday, June 14, from 11:45–13:30 CEST.
• Real-world data looking at the risk for infection-related hospitalization and associated medical costs for patients in the United States treated with abatacept versus other targeted disease-modifying, anti-rheumatic drugs (tDMARDs). The full data analysis will be featured in a poster presentation on Thursday, June 14, from 11:45–13:30 CEST.

“The research that Bristol-Myers Squibb is presenting at EULAR 2018 speaks to our focus on helping address the burden of destructive autoimmune diseases for patients and physicians,” said Brian Gavin, PhD, Development Lead, Orencia and Nulojix, Bristol-Myers Squibb. “We are building on a 20-year research commitment to defining the role of immunomodulation in treating autoimmune diseases and researching clinically meaningful biomarkers that can help guide personalized treatment approaches to conditions like rheumatoid arthritis.” The full listing of abstracts Bristol-Myers Squibb will present at EULAR 2018, including data and analyses in rheumatoid arthritis, juvenile idiopathic arthritis, lupus nephritis and other disease types follows. – Medical Buyer Bureau